Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study-Reference-Cited by-同舟云学术

Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study

Published:2020-12-07 Issue:5 Volume:56 Page:1171-1179
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Styczyński Jan^ORCID,Tridello Gloria,Xhaard Alienor,Medinger Michael,Mielke Stephan,Taskinen Mervi,Blijlevens Nicole,Rodriguez M. Aranzazu Bermudez,Solano Carlos,Nikolousis Emmanouil,Biffi Alessandra,Groll Andreas H.,Junghanss Christian,Tsirigotis Panagiotis^ORCID,Lioure Bruno,Šrámek Jiří,Holler Ernst,Galaverna Federica,Fagioli Franca^ORCID,Knelange Nina,Wendel Lotus,Gil Lidia,de la Camara Rafael^ORCID,Mikulska Malgorzata^ORCID,Ljungman Per^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/s41409-020-01166-w.pdf

Reference20 articles.

1. Green ML, Leisenring W, Xie H, Mast TC, Cui Y, Sandmaier BM, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3:e119–127. https://doi.org/10.1016/S2352-3026(15)00289-6.

2. Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J, et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood. 2013;122:3359–64. https://doi.org/10.1182/blood-2013-05-499830.

3. Ljungman P, Brand R, Hoek J, de la Camara R, Cordonnier C, Einsele H, et al. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. Clin Infect Dis. 2014;59:473–81. https://doi.org/10.1093/cid/ciu364.

4. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis. 2008;47:1041–50. https://doi.org/10.1086/591969.

5. Yong MK, Slavin MA, Kontoyiannis DP. Invasive fungal disease and cytomegalovirus infection: is there an association? Curr Opin Infect Dis. 2018;31:481–9. https://doi.org/10.1097/QCO.0000000000000502.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A single center experience;European Journal of Haematology;2024-06-21

2. Adenovirus‐ and cytomegalovirus‐specific adoptive T‐cell therapy in the context of hematologic cell transplant or HIV infection – A single‐center experience;Transplant Infectious Disease;2024-06-03

3. Cytomegalovirus Reactivations in Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Matched and Haploidentical Donors with Post-Transplantation Cyclophosphamide;Transplantation and Cellular Therapy;2024-05

4. Letermovir for cytomegalovirus infection in allogeneic hematopoietic stem-cell transplantation: tips and notes for effective use in clinical practice;Expert Review of Anti-infective Therapy;2024-03

5. Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients;Journal of the Pediatric Infectious Diseases Society;2024-02-01